Biologic Exclusivity Under the BPCIA: The 12-Year Standard Under the Biologics Price Competition and Innovation Act (BPCIA), reference biological products receive 12 years of exclusivity from approval, during which biosimilar applications cannot receive FDA approval
As for the GLP-1 albumin fusions, exposure to CPA resulted in removal of L585 and reduced FcRn binding of the WT albumin fusions, but not for the QMP-engineered counterparts (Supplementary Fig
GLP-1 analogues, like semaglutide (Wegovy), liraglutide (Ozempic), oral semaglutide (Rybelsus), retatrutide, and tirzepatide, have garnered attention for their remarkable impact on weight management
What is the best app to track GLP-1 medications
Diabetes Therapy, 15(2), 345357
Always speak to your doctor before stopping any treatment